Trials / Completed
CompletedNCT00446784
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CE-224,535 | |
| DRUG | Methotrexate |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-03-13
- Last updated
- 2011-05-23
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00446784. Inclusion in this directory is not an endorsement.